A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
Clinical trial NCT02138747 · COMPLETED
Trial details
- NCT number
- NCT02138747
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-24
- Primary completion
- 2015-10-29
- Enrollment
- 376
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.